PFE vs PSTV

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Plus Therapeutics (PSTV) retains its high-risk, high-reward profile, but its immediate financial health has significantly improved since the last analysis. The company's cash position increased to over $16 million in 2025, moving stockholders' equity from negative to positive $3.9 million, substantially extending its cash runway. This addresses the primary financial risk previously identified. Fur...